Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 790,000 | 2.6% |
| Gross Profit | -7.6M | 0.3% |
| Cost of Revenue | 8.4M | 0.6% |
| Operating expense | 36M | 0.2% |
| Net Income | -31M | 0.1% |
| EBITDA | -35M | 8.5% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 389M | 6.7% |
| Total Liabilities | 193M | 0.7% |
| Total Equity | 196M | 11.9% |
| Shares Outstanding | 85M | 0% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -28M | 3.7% |
| Cash from investing | 39M | 215.8% |
| Cash from financing | 270,000 | 99.5% |
EPS
Financial Highlights for Century Therapeutics in Q3 '24
Century Therapeutics reported a revenue of 790,000, which is a 2.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -7.6M, marking a -0.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 8.4M, a 0.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 36M, showing a 0.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -31M, showing a -0.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -35M, showing a -8.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Century Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
